Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
相关临床试验
51
20 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
18
35.3%
已完成
16
31.4%
Enrolling By Invitation
1
2.0%
尚未招募
1
2.0%
招募中
14
27.4%
Unknown
1
2.0%
- The Institute for Clinical and Economic Review (ICER) released a report recommending greater transparency in the FDA's accelerated approval pathway for drugs treating serious conditions with no approved treatments. - The report proposes implementing a scoring system for clinical trial quality, requiring advisory committees for reviews, and strengthening surrogate endpoint selection to improve pathway performance. - Recent accelerated approvals include Denali Therapeutics' Avlayah for rare disease and Rocket Pharmaceuticals' gene therapy Kresladi, while controversial cases like Biogen's withdrawn Aduhelm highlight ongoing concerns about evidence standards.
- Biognosys Group has announced a collaboration with The Michael J. Fox Foundation to develop biomarker assays for LRRK2, the most common genetic risk factor for late-onset Parkinson's disease. - The partnership will support MJFF's LRRK2 Investigative Therapeutics Exchange (LITE), a global initiative involving more than 50 academic, industry and clinical partners working to accelerate LRRK2-targeted therapy development. - The collaboration aims to address a significant barrier in Parkinson's drug development: the lack of sensitive and reliable biomarkers to measure LRRK2 expression and activity as treatment indicators. - Biognosys will utilize its SISCAPA and TrueSignature ultra-sensitive proteomics platforms to develop quantitative biomarker assays that could guide therapy development and identify patients suitable for LRRK2-directed treatments.
- Dublin-based Aerska raised $39 million in Series A funding led by EQT Dementia Fund and age1 to advance its antibody-oligo conjugate platform for delivering RNA therapies to the brain. - The company's proprietary "brain shuttle" technology aims to overcome the blood-brain barrier challenge by enabling systemic administration of RNAi therapies for neurological diseases. - Aerska is initially focusing on genetically-driven forms of Alzheimer's disease and other brain disorders, targeting upstream genetic interventions rather than symptom management. - The funding brings Aerska's total raised capital to $60 million and positions the company to compete in the growing brain delivery technology space alongside major pharmaceutical partnerships.
- Eight biotech companies raised a record $3.5 billion in a single night following the American Society of Hematology conference, marking the busiest day ever in biotech fundraising. - Terns Pharmaceutical led the surge with a $650 million offering after presenting Phase I leukemia trial data showing 64% response rates, with potential peak sales projected at $2.5 billion. - Fulcrum Therapeutics raised $175 million following positive Phase Ib results for its sickle cell disease treatment in expectant mothers, demonstrating meaningful increases in fetal hemoglobin levels. - The fundraising wave reflects strong biotech sector performance with the NYSE Arca Biotechnology Index up 27% year-to-date, driven by positive trial results and increased M&A activity.
- Bristol Myers Squibb's Breyanzi received FDA approval for treating relapsed or refractory marginal zone lymphoma, becoming the first cell therapy available for this rare lymphatic tumor. - The approval represents Breyanzi's fifth indication and addresses a significant unmet need in marginal zone lymphoma, which accounts for approximately 7% of all B-cell non-Hodgkin lymphoma cases. - Breyanzi has demonstrated strong commercial performance with $747 million in sales in 2024 and $966 million over the first nine months of 2025.
- Denali Therapeutics and Royalty Pharma announced a $275 million synthetic royalty funding agreement based on future sales of tividenofusp alfa, an investigational enzyme replacement therapy for Hunter syndrome. - The therapy utilizes Denali's proprietary TransportVehicle platform to cross the blood-brain barrier and is currently under FDA review for accelerated approval with a PDUFA target date of April 5, 2026. - Under the agreement, Royalty Pharma will pay $200 million at closing and an additional $75 million upon European approval, receiving a 9.25% royalty on worldwide net sales. - The deal validates the potential of tividenofusp alfa to address significant unmet needs in both cognitive and physical manifestations of Hunter syndrome.
- Industry experts at the 2025 Clinical Trial Supply West Coast conference identified risk management as critical for pharmaceutical supply chains amid rising tariffs and AI disruption. - President Trump's tariffs on pharmaceutical imports, including a 15% rate on EU products with potential increases to 250%, are forcing companies to develop backup sourcing strategies. - Artificial intelligence is accelerating the shift from site-centric to patient-centric clinical trials, though human input remains essential for interventional trials with scarce data. - Regulatory changes including FDA guidance on decentralized trials and diversity requirements are reshaping clinical trial operations and supply chain planning.
- Over 10 companies are developing 12+ RIPK1 inhibitor therapies targeting inflammatory and neurodegenerative diseases, with key players including Sanofi, Rigel Pharmaceuticals, and GenFleet Therapeutics advancing promising candidates. - Sanofi discontinued its Phase 2 trial of oditrasertib in multiple sclerosis after failing to meet primary endpoints, highlighting the challenges in targeting neurodegeneration with RIPK1 inhibition. - Leading pipeline candidates include SAR443122 for cutaneous lupus and ulcerative colitis, GFH312 as China's first clinical-stage RIPK1 inhibitor, and R552 developed through Rigel's collaboration with Eli Lilly. - RIPK1 inhibitors represent a novel therapeutic approach by blocking inflammation and cell death pathways, offering potential treatments for autoimmune disorders, neurodegenerative conditions, and inflammatory diseases.
- Voyager Therapeutics has launched a new gene therapy program targeting APOE4, the strongest genetic risk factor for Alzheimer's disease, using its proprietary TRACER capsid technology for intravenous delivery. - The bifunctional therapy simultaneously reduces harmful APOE4 expression while delivering protective APOE2 variant, achieving 90% reduction of APOE4 in key brain regions in preclinical studies. - The company's expanded Alzheimer's franchise now includes four wholly-owned assets targeting tau, amyloid, and APOE pathways, with first human data expected in late 2025. - Despite promising preclinical results, the stock has declined 67% year-to-date as investors weigh execution risks against the potential for breakthrough treatment in a market projected to exceed $50 billion by 2030.
- Alector's Latozinemab (AL001) leads the frontotemporal dementia pipeline as a monoclonal antibody targeting progranulin deficiency, currently in pivotal Phase III trials with potential approval by 2026-2027. - Gene therapy companies AviadoBio and Passage Bio are developing AAV-based treatments AVB-101 and PBFT02 to restore progranulin expression through one-time administration, with readouts expected in late 2027 or early 2028. - The FTD therapeutic landscape is shifting from symptom management to disease modification, with multiple approaches including monoclonal antibodies, gene therapies, and oral small molecules targeting genetic biomarkers. - By 2028, the FTD market may include personalized therapies aligned with genetic profiles, potentially transforming clinical outcomes for patients aged 45-64 who currently lack disease-modifying treatment options.
